Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 5,128 matching trials from the live ClinicalTrials.gov search.

Filters: San Francisco, California Clear all

Conditions: Complex Regional Pain Syndrome (CRPS)
Interventions: Dorsal Root Ganglion (DRG) Stimulation (Axium™ Neurostimulator System), Dorsal Root Ganglion (DRG) Stimulation (Proclaim™ Neurostimulator System); Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 22 Years to 75 Years
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 44
States / cities: Scottsdale, Arizona • Camarillo, California • Larkspur, California + 38 more

Conditions: Osteoporosis
Interventions: PTH(1-84), Ibandronate, Placebo injection, Placebo pills; Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 55 Years to 75 Years · Female only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Sarcoidosis
Interventions: Acthar gel; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Neoplasms
Interventions: Smoked Marijuana; Drug
Lead sponsor: Center for Medicinal Cannabis Research; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Shift-Work Sleep Disorder
Interventions: NIOSH shiftwork booklet, Sleep Enhancement Training System; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 40 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cardiopulmonary
Interventions: Not listed
Lead sponsor: Prolaio; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 15
States / cities: Scottsdale, Arizona • Palo Alto, California • San Francisco, California + 11 more

Conditions: Dysequilibrium Syndrome, ESRD, Hyperkalemia, Metabolic Acidosis
Interventions: Urea in the dialysate; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pheochromocytoma, Paraganglioma
Interventions: 131 I-Metaiodobenzylguanidine (131 I-MIBG); Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 2 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Glioma
Interventions: Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging, Radiation Therapy, Chemotherapy; Radiation · Procedure · Drug
Lead sponsor: Susan Chang; Other
Eligibility: 19 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Parkinson Disease, Depression, Anxiety
Interventions: Psilocybin therapy; Drug
Lead sponsor: Joshua Woolley, MD, PhD; Other
Eligibility: 40 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma
Interventions: SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS); Combination Product
Lead sponsor: SonALAsense, Inc.; Industry
Eligibility: 5 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: San Francisco, California • Washington D.C., District of Columbia • Miami, Florida

Conditions: Fetal Structural Anomalies
Interventions: Genomic Sequencer; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 64 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Acute Kidney Injury, Ischemia Reperfusion Injury
Interventions: Valproic acid, Isotonic saline solution; Drug
Lead sponsor: Westat; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: San Francisco, California • Denver, Colorado • Dallas, Texas + 1 more

Conditions: Obesity, Metabolic Syndrome
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hepatitis C, Chronic, HIV CDC Category A1
Interventions: Sofosbuvir + Simeprevir; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Lupus Nephritis
Interventions: Rituximab, Cyclophosphamide, Prednisone, Methylprednisolone, Diphenhydramine, Acetaminophen, Belimumab; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more

Conditions: Breast Cancer
Interventions: Arm A: Gedatolisib + Palbociclib + Fulvestrant, Arm B: Ribociclib + Fulvestrant, Arm C: Gedatolisib + Palbociclib + Letrozole, Arm D: Ribociclib + Letrozole; Drug
Lead sponsor: Celcuity Inc; Industry
Eligibility: 18 Years and older
Enrollment: 1,180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 30
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Duarte, California + 27 more

Conditions: Hepatitis, Viral, Human, HIV Infections
Interventions: Testing, Education, & Counseling (TEC), Hepatitis Care Coordination (HCC); Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 489 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: San Francisco, California • New York, New York

Conditions: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions: Abiraterone Acetate, Androgen deprivation therapy, Cabazitaxel, Prednisone; Drug
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 665
States / cities: Fairbanks, Alaska • Goodyear, Arizona • Kingman, Arizona + 437 more

Conditions: Non-Muscle Invasive Bladder Neoplasms
Interventions: TAR-200, Mitomycin C, Gemcitabine; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 29
States / cities: Little Rock, Arkansas • Los Alamitos, California • Los Angeles, California + 24 more

Conditions: Glioblastoma, Recurrent Glioblastoma, GBM
Interventions: SonoCloud-9 (SC9), Carboplatin, Lomustine, Temozolomide; Device · Drug
Lead sponsor: CarThera; Industry
Eligibility: 18 Years and older
Enrollment: 560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 23
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 16 more

Conditions: Lymphoma
Interventions: carmustine, cyclophosphamide, etoposide, mesna, peripheral blood stem cell transplantation; Drug · Procedure
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 21 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2007
U.S. locations: 206
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more

Conditions: Autoimmune Diseases
Interventions: Efalizumab; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breast Cancer
Interventions: mammography; Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 311
States / cities: Fairbanks, Alaska • Scottsdale, Arizona • Fort Smith, Arkansas + 222 more

Search by objective public record fields.

TARGET Post-Approval Study

PTH & Ibandronate Combination Study (PICS)

Use of CXCL9 as a Biomarker of Acthar Efficacy

Marijuana for Cancer Pain

Sleep Enhancement Training Study for Experienced Shiftworkers

Observational, Non-Interventional Study Supporting Validation of eVO2peak Using Results in Patients Receiving Standard of Care Cardiopulmonary Exercise Tests (CPET)

Adding Urea to the Final Dialysis Fluid

Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma

Hyperpolarized Imaging in Diagnosing Participants With Glioma

Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease

A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Patients with DIPG

Genomic Sequencing for Evaluation of Fetal Structural Anomalies

Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients

Is Fructose Linked to Adiposity in Babies?

A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C

Rituximab and Belimumab for Lupus Nephritis

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

HIV and Hepatitis Care Coordination in Methadone Treatment

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's Lymphoma

Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg Cells

Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or Anastrozole